Diamyd To Reach Milestone In Phase III Program For Diabetes Vaccine
Diamyd Medical has reported that 90% of the total 320 children and adolescents with type 1 diabetes for the European phase III study with the diabetes vaccine –
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.